A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

Status:
Terminated

Trial end date:
2018-11-21

Target enrollment:

Participant gender:

A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.

Phase 1

Novartis Pharmaceuticals